Budesonide Once vs Twice Daily for EoE Remission
Treatments studied
Part of Blood & lymphatic, Digestive system, Immune system & allergy clinical trials.
This study tests whether a budesonide tablet that dissolves in the mouth works as well when taken once a day compared to twice a day for treating active eosinophilic esophagitis (EoE). It aims to help people with EoE achieve remission (feeling better and less inflammation).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of eosinophilic esophagitis (EoE) with active symptoms and signs of inflammation.
- You cannot have certain other conditions that affect the esophagus, like GERD, achalasia, or a history of esophageal surgery.
- You cannot have active infections (like candida in the esophagus) or other serious illnesses (like cancer in the last 5 years, liver disease, or uncontrolled diabetes).
- If you are a woman able to have children, you must have a negative pregnancy test and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatments for EoE that has caused narrowing in the esophagus: dupilumab (a biologic injection) versus a topical corticosteroid (a swallowed steroid). It aims to see which works better for teens and young adults to improve swallowing and reduce inflammation.
This trial tests an intervention meant to improve how well adults with eosinophilic esophagitis (EoE) follow their ongoing treatment plan. It may help you stay on your medicine and get better symptom control by making adherence easier.
This Phase 1/2 study tests EP-104GI in adults with eosinophilic esophagitis (EoE), a condition where certain immune cells cause inflammation in the food pipe. It may help improve symptoms and inflammation, and the study also includes a part where people who do well can switch to the active drug.
This study tests whether a medication called upadacitinib can help people with eosinophilic esophagitis (a condition where too many white blood cells called eosinophils build up in the food tube) who are not getting better with their current steroid treatment. The medication works by reducing inflammation in the esophagus.
This study looks at how well Dupilumab works over time in people aged 12 and older with eosinophilic esophagitis (EoE) whose symptoms are not well controlled by standard treatments. It aims to understand the medicine's effects in everyday medical practice.
This study compares two medicines—Eohilia (an oral steroid) and Dupixent (an injectable biologic)—to see which one better helps widen the esophagus in people with eosinophilic esophagitis (EoE). It may help you if you have active EoE and are looking for a new treatment option.
Hear when a new Eosinophilic Esophagitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.